Rifampicin | German Center for Infection Research

Short description

Rifampicin is an antibiotic especially used to treat mycobacterial infections.

Detailed description

Rifampicin inhibits the RNA polymerase – a bacterial enzyme needed for protein production.

Pills dropping from a medicine bottle into the palm of a hand

Open letter: Experts call for urgent expansion of Pretomanid label

A coalition of leading tuberculosis (TB) experts and medical societies—including scientists from the German Center of Infection Research (DZIF)—is calling for an urgent expansion of the European

Aug 2024

Open Forum Infect Dis

Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa

Autoren

Centner CM et al.

May 2024

Respiration

Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland

Autoren

Otto-Knapp R et al.

Jun 2024

Clin Microbiol Infect

Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al

Autoren

Friesen I et al.

Jun 2024

Clin Microbiol Infect

Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response

Autoren

Lange C et al.

Mar 2024

Clin Microbiol Infect

Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe

Autoren

Günther G et al.

Nov 2023

Pneumologie

[Treatment of MDR, pre-XDR, XDR and rifampicin resistant TB or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment to the Sk2-Guideline: TB in adulthood of the DZK on behalf of the DGP]

Autoren

Otto-Knapp R et al.

Oct 2023

Nat Commun

Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis

Autoren

Menzies NA et al.

Feb 2024

Nat Med

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

Autoren

Diacon AH et al.

A lab technician pipettes a sample into a sequencing device.

When (new) drugs don’t work: Mozambique faces alarming multidrug-resistant tuberculosis epidemic

With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major